Search
Search Results
##search.searchResults.foundPlural##
-
Should every patient with MDS get iron chelation – probably yes.
2421PDF: 1009HTML: 401 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
3198PDF: 942HTML: 6619Untitled: 282Untitled: 241Untitled: 259Untitled: 265 -
-
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1511PDF: 853HTML: 373 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1268PDF: 810HTML: 1536Figure 1: 250Figure 2: 252 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3849PDF: 969HTML: 6887 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2702PDF: 869HTML: 5388 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
2003PDF: 1235HTML: 347 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
2210PDF: 891HTML: 266 -
SIMPLE PERIPHERAL BLOOD SMEAR FINDINGS OF COVID-19 PATIENTS PROVIDE INFORMATION ABOUT THE SEVERITY OF THE DISEASE AND THE DURATION OF HOSPITAL STAY. Peripheral blood smear and COVID-19 severity.
3699PDF: 1280HTML: 520 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3280PDF: 1687HTML: 378 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
4100PDF: 819HTML: 1898 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2291PDF: 1653HTML: 701 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
1122PDF: 1076Suppl. Files: 675HTML: 198 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7939PDF: 2516HTML: 2151Table 1.: 272Table 2.: 282Table 3.: 263Table 4.: 260 -
The significance of purity: Leukaemias involving the erythroid lineage Erythroid lineage leukemia
905PDF: 457HTML: 376 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2650PDF: 1792HTML: 698 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2810PDF: 827HTML: 2333 -
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1272PDF: 881HTML: 3421 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1555PDF: 1401HTML: 121 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1714PDF: 1130HTML: 497 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1671PDF: 1180HTML: 273 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2221PDF: 1383HTML: 3517 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1414PDF: 1116HTML: 447 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
1222PDF: 647Suppl. Files: 151HTML: 534







